LRRK2 is a target of interest for Parkinson’s disease (e.g. DNL-151), but development had been slowed by concerns about potential lung toxicity of LRRK2 inhibitors. A Phase I study…
Drug Hunter
Drug Hunter
LRRK2 is a target of interest for Parkinson’s disease (e.g. DNL-151), but development had been slowed by concerns about potential lung toxicity of LRRK2 inhibitors. A Phase I study…